Mustang Bio, Inc. (MBIO) Stock Price, Financials & Summary

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

3.7x

Market Cap

$4.04M

MomentumView details →

1D Return

−4.68%

YTD Return

−45.06%

RSI (14)

39.7

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

3.7x

Market Cap

$4.04M

RSI (14)

39.7

MomentumView details →

1D Return

−4.68%

YTD Return

−45.06%

SummaryUpdated Jun 1, 2026

Mustang Bio, Inc. (NASDAQ:MBIO) is a clinical-stage biopharmaceutical company founded in 2015 and headquartered in Worcester, Massachusetts. The company went public in August 2017 and focuses on developing cutting-edge cell and gene therapies designed to treat hematologic cancers, solid tumors, and rare genetic diseases. Mustang Bio operates in the highly specialized biotechnology sector, working to translate breakthrough medical research into potential cures for patients with limited treatment options.

Ask drillr about Mustang Bio, Inc. →

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

−40.20%

ROA (TTM)

−19.43%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

—

EPS YoY

+65.22%

FCF YoY

—

Revenue CAGR 3Y

—

EPS CAGR 3Y

+84.82%

EBITDA YoY

+2.41%

EarningsView details →

EPS (Actual)

−$0.16

EPS Surprise

99.89%

Beats (12Q)

6/12

Next Q EPS Est

−$140.00

Avg Surprise (4Q)

−80.25%

Rev Surprise

—

Capital & dividendView details →

Debt/Equity

0.00x

Current Ratio

1.97x

Quick Ratio

1.97x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

Financials snapshotView financials →

Revenue (TTM)

0.00

Net Income (TTM)

−3.03M

Op. CF (TTM)

−4.51M

Next earningsNov 18, 2026 →

Latest newsMore news →

No recent news for MBIO.

Similar companies

BioRestorative Therapies, Inc.BRTX OSR Holdings, Inc.OSRH Silo Pharma, Inc.SILO Revelation Biosciences, Inc.REVB Aspire Biopharma Holdings, Inc.ASBPW XORTX Therapeutics Inc.XRTX Find similar companies →

Latest newsMore news →

No recent news for MBIO.